Osaic Holdings’s Prelude Therapeutics PRLD Stock Holding History

Osaic Holdings’s Portfolio PRLD Stock Details PRLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$2.85K	–	7554
2023 Q1	$2.85K	Hold	500	–	–	﹤0.01%	6579
2022 Q4	$3K	Hold	500	–	–	﹤0.01%	6534
2022 Q3	$3K	Hold	500	–	–	﹤0.01%	6654
2022 Q2	$3K	Buy	500 +135	+37%	+$687	﹤0.01%	6747
2022 Q1	$2K	Buy	365 +25	+7%	+$229	﹤0.01%	6903
2021 Q4	$4K	Hold	340	–	–	﹤0.01%	6767
2021 Q3	$11K	Hold	340	–	–	﹤0.01%	6151
2021 Q2	$10K	Hold	340	–	–	﹤0.01%	6075
2021 Q1	$15K	Buy	+340	New	+$22.6K	﹤0.01%	5658

Other funds holding PRLD

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Osaic Holdings's PRLD Position: Q2 2023 in Review

Osaic Holdings sold out of Prelude Therapeutics (PRLD) in Q2 2023, closing a stake of 500 shares — an estimated $2.85K sold.

Osaic Holdings first reported a position in PRLD in Q1 2021 and held it in 9 quarters. The position peaked at $15K in Q1 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q2 2023.

Osaic Holdings reported no remaining Prelude Therapeutics position as of Q2 2023 after selling out during the quarter.
Osaic Holdings sold 500 Prelude Therapeutics shares in Q2 2023, an estimated $2.85K.
Osaic Holdings first reported a position in Prelude Therapeutics in Q1 2021 and held it in 9 quarters.
Osaic Holdings's Prelude Therapeutics position peaked at $15K in Q1 2021.
55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q2 2023.

Based on Osaic Holdings's 13F filing for Q2 2023, filed 10 Aug 2023.